Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07615712 · ClinicalTrials.gov registry record
PPD™ CorEvitas™ Psoriasis (PSO) Rapid Response Non-Interventional Study
A clinical trial, sponsored by CorEvitas.
- Recruiting
- Registry status
- 2,500
- Enrollment target
NCT07615712 is a clinical trial that is actively recruiting participants, run by CorEvitas. The registered enrollment target is 2,500 participants.
The verdict
NCT07615712 is actively recruiting participants, sponsored by CorEvitas.
- RECRUITING
- Registry status
- 2,500 participants
- Enrollment target
Study Summary
This is a 16-week prospective, single-arm cohort, study of patients initiating advanced therapy for the treatment of moderate-to-severe plaque PSO. Eligible patients must be willing to be seen in-person by their treating physician for a Baseline visit (with first dose of the advanced therapy occurring within 14 days), and at 2 (+/- 5 days), 4 (+/- 5 days), and 16 weeks (+14 days) calculated based on date of first dose of the advanced therapy and must provide informed consent prior to enrolling in the study or completing study-specific questionnaires or procedures. Data will be collected from both subjects and their treating dermatology provider at predetermined scheduled intervals (Baseline, Week 2, Week 4, and Week 16) using a structured and standardized data collection tool.
Interventions
- OTHER Observational (Non-Interventional) Registry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,500 participants |
| Start Date | 2025-04-30 |
| Est. Completion | 2035-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07615712
The ClinicalTrials.gov registry entry for NCT07615712 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CorEvitas, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Observational (Non-Interventional) Registry is the first listed.
NCT07615712 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07615712 about?
NCT07615712 is a clinical study titled "PPD™ CorEvitas™ Psoriasis (PSO) Rapid Response Non-Interventional Study". This is a 16-week prospective, single-arm cohort, study of patients initiating advanced therapy for the treatment of moderate-to-severe plaque PSO. Eligible patients must be willing to be seen in-person by their treating physician for a Baseline visit (with first dose of the advanced therapy occurri...
What is the current status of trial NCT07615712?
This trial is currently recruiting. The enrollment target is 2,500 participants. The study started on 2025-04-30. Estimated completion is 2035-12.
What interventions are being tested in trial NCT07615712?
The interventions under investigation include: Observational (Non-Interventional) Registry (OTHER).
Who is sponsoring clinical trial NCT07615712?
This trial is sponsored by CorEvitas, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.